Abstract
Background: Clinical guidelines recommend that patients using inhaled corticosteroids should rinse their mouth following inhalation. There is however, a paucity of research regarding patient implementation of this recommendation and the impact it has on the occurrence of adverse effects. Objective: The aim of this study was to determine how well patients implement mouth rinsing after using inhaled corticosteroids in practice and their understanding of the rationale, information sources and the impact of mouth rinsing on adverse effects. Setting: Australians aged 18 years and over with a diagnosis of asthma and/or chronic obstructive pulmonary disease who were currently using an inhaled corticosteroid. Method: Participants were recruited via Facebook to complete an online survey. Main outcome measure: Implementation of a mouth rinse which aligned to current guideline recommendations. Results: Of 380 eligible responses, 30.5% of patients reported suboptimal mouth rinsing after using inhaled corticosteroids. Receiving advice on mouth rinsing from a healthcare professional increased the likelihood of correct implementation (P < 0.001) and improved patient understanding of the rationale (P = 0.01). Whilst most (90.0%) patients were aware rinsing may reduce oropharyngeal adverse effects, few (5.5%) were aware of its potential to reduce systemic adverse effects. Patients were more likely to report their rinsing procedure had a positive impact if they had experienced oral candidiasis (P < 0.001) or sore mouth/throat (P = 0.01), compared to cough or hoarse voice. Conclusion: Almost one-third of patients reported a suboptimal mouth rinsing procedure after using an inhaled corticosteroid. Interventions are required to improve awareness and correct implementation of mouth rinsing.
Similar content being viewed by others
Availability of data and material
The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.
Code availability
Not applicable.
References
National Asthma Council Australia. Australian Asthma Handbook. Melbourne: National Asthma Council Australia 2018. http://www.asthmahandbook.org.au/. Accessed 5 July 2018.
Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med. 2000;343(5):332–6.
Lung Foundation Australia. Stepwise Management of Stable COPD. Milton, Queensland: Lung Foundation Australia; 2017. https://lungfoundation.com.au/wp-content/uploads/2017/10/LFA-Stepwise-Management-of-COPD_0817_WEB.pdf. Accessed 21 Sept 2018.
Buhl R. Local oropharyngeal side effects of inhaled corticosteroids in patients with asthma. Allergy. 2006;61(5):518–26.
Horita N, To M, Araki K, Haruki K, To Y. Risk factors of local oropharyngeal and laryngeal adverse effects from use of single inhaled corticosteroids and long-acting beta-agonists. Allergol Int. 2012;61(4):583–8.
Roland NJ, Bhalla RK, Earis J. The local side effects of inhaled corticosteroids: current understanding and review of the literature. Chest. 2004;126(1):213–9.
Foster JM, van Sonderen E, Lee AJ, Sanderman R, Dijkstra A, Postma DS, et al. A self-rating scale for patient-perceived side effects of inhaled corticosteroids. Respir Res. 2006;7:131.
Fitzgerald JM, Chan CK, Holroyde MC, Boulet LP. The CASE survey: patient and physician perceptions regarding asthma medication use and associated oropharyngeal symptoms. Can Respir J. 2008;15(1):27–32.
Pinto CR, Almeida NR, Marques TS, Yamamura LL, Costa LA, Souza-Machado A. Local adverse effects associated with the use of inhaled corticosteroids in patients with moderate or severe asthma. J Bras Pneumol. 2013;39(4):409–17.
Kajiwara A, Kita A, Saruwatari J, Morita K, Oniki K, Yamamura M, et al. Absence of gargling affects topical adverse symptoms caused by inhaled corticosteroids in females. J Asthma. 2014;51(2):221–4.
Sansom LN. Australian pharmaceutical formulary and handbook. 24th ed. Canberra: Pharmaceutical Society of Australia; 2019.
Selroos O, Halme M. Effect of a volumatic spacer and mouth rinsing on systemic absorption of inhaled corticosteroids from a metered dose inhaler and dry powder inhaler. Thorax. 1991;46(12):891–4.
Yokoyama H, Yamamura Y, Ozeki T, Iga T, Yamada Y. Influence of mouth washing procedures on the removal of drug residues following inhalation of corticosteroids. Biol Pharm Bull. 2006;29(9):1923–5.
MIMs Australia. Medicines Information. MIMs Australia 2019. https://www.emims.com.au/Australia/drug/search. Accessed 2 Apr 2019.
Global Institute for Asthma. Global Strategy for Asthma Management and Prevention. Fontana, United States of America; Global Institute for Asthma 2020. https://ginasthma.org/wp-content/uploads/2020/06/GINA-2020-report_20_06_04-1-wms.pdf. Accessed 1 Sept 2020.
Yokoyama H, Yamamura Y, Ozeki T, Iga T, Yamada Y. Effects of mouth washing procedures on removal of budesonide inhaled by using Turbuhaler. Yakugaku Zasshi. 2007;127(8):1245–9.
Capanoglu M, Dibek Misirlioglu E, Toyran M, Civelek E, Kocabas CN. Evaluation of inhaler technique, adherence to therapy and their effect on disease control among children with asthma using metered dose or dry powder inhalers. J Asthma. 2015;52(8):838–45.
Sanchis J, Gich I, Pedersen S. Systematic review of errors in inhaler use: has patient technique improved over time? Chest. 2016;150(2):394–406.
Driesenaar JA, De Smet P, van Hulten R, Hu L, van Dulmen S. Communication during counseling sessions about inhaled corticosteroids at the community pharmacy. Patient Prefer Adherence. 2016;10(1):2239–54.
Australian Institute of Health and Welfare. Chronic respiratory conditions. Canberra, Australia: Australian Government 2018. https://www.aihw.gov.au/reports-statistics/health-conditions-disability-deaths/chronic-respiratory-conditions/overview. Accessed 26 Sept 2018.
Survey Monkey. Survey Sample Size. Survey Mokey, 2017. https://www.surveymonkey.com/mp/sample-size/. Accessed 26 Sept 2017.
Cooper V, Metcalf L, Versnel J, Upton J, Walker S, Horne R. Patient-reported side effects, concerns and adherence to corticosteroid treatment for asthma, and comparison with physician estimates of side-effect prevalence: a UK-wide, cross-sectional study. NPJ Prim Care Respir Med. 2015;25:15026.
Australian Medicines Handbook. Adelaide. South Australia: Australian Medicines Handbook; 2019.
Foster JM, Aucott L, van der Werf RH, van der Meijden MJ, Schraa G, Postma DS, et al. Higher patient perceived side effects related to higher daily doses of inhaled corticosteroids in the community: a cross-sectional analysis. Respir Med. 2006;100(8):1318–36.
Souza ML, Meneghini AC, Ferraz E, Vianna EO, Borges MC. Knowledge of and technique for using inhalation devices among asthma patients and COPD patients. J Bras Pneumol. 2009;35(9):824–31.
Bosnic-Anticevich SZ, Sinha H, So S, Reddel HK. Metered-dose inhaler technique: the effect of two educational interventions delivered in community pharmacy over time. J Asthma. 2010;47(3):251–6.
Basheti IA, Armour CL, Bosnic-Anticevich SZ, Reddel HK. Evaluation of a novel educational strategy, including inhaler-based reminder labels, to improve asthma inhaler technique. Patient Educ Couns. 2008;72(1):26–33.
Purohit AN, Patel PP, Gandhi AM, Desai MK. An evaluation of impact of educational interventions on the technique of use of metered-dose inhaler by patients. Indian J Pharmacol. 2017;49(2):194–200.
Foland AP, Stern T, Ramacciotti T, Martin J, Gilbert I, Cohn RC. Improvement of metered-dose inhaler administration technique: the effect of training sessions at a specialized pediatric asthma compliance and technique clinic. Curr Ther Res. 2002;63(2):142–7.
van der Palen J, Klein JJ, Kerkhoff AH, van Herwaarden CL, Seydel ER. Evaluation of the long-term effectiveness of three instruction modes for inhaling medicines. Patient Educ Couns. 1997;32(1):87–95.
Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med. 2010;123(11):1001–6.
Gonzalez AV, Coulombe J, Ernst P, Suissa S. Long-term use of inhaled corticosteroids in COPD and the risk of fracture. Chest. 2018;153(2):321–8.
Dreizen S. Oral candidiasis. Am J Med. 1984;77(4):28–33.
Chung KF, Pavord ID. Prevalence, pathogenesis, and causes of chronic cough. Lancet. 2008;371(9621):1364–74.
Toogood JH, Jennings B, Greenway RW, Chuang L. Candidiasis and dysphonia complicating beclomethasone treatment of asthma. J Allergy Clin Immunol. 1980;65(2):145–53.
Williamson I, Matusiewicz S, Brown P, Greening A, Crompton G. Frequency of voice problems and cough in patients using pressurized aerosol inhaled steroid preparations. Eur Respir J. 1995;8(4):590–2.
Gallivan GJ, Gallivan KH, Gallivan HK. Inhaled corticosteroids: hazardous effects on voice-an update. J Voice. 2007;21(1):101–11.
Acknowledgements
Peter Gee, University of Tasmania for assistance with survey development. National Asthma Council and Asthma Australia for assistance in raising awareness of the survey.
Funding
The study was funded by the School of Pharmacy and Pharmacology, University of Tasmania, Hobart, Tasmania, Australia, 7001.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
None.
Consent to participate
By submitting the survey participants provided their consent.
Consent for publication
Not applicable.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Johnstone, L.K., Bereznicki, B.J., Jacobson, G. et al. Implementation of mouth rinsing after use of inhaled corticosteroids in Australia. Int J Clin Pharm 43, 549–555 (2021). https://doi.org/10.1007/s11096-020-01161-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11096-020-01161-7